Commonwealth Equity Services
CCCC icon

Commonwealth Equity Services’s C4 Therapeutics CCCC Stock Holding History

Commonwealth Equity Services’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-20,510
Closed -$46K – 4303
2025
Q3 		$46K Sell
20,510
-601
-3% -$1.44K ﹤0.01% 4168
2025
Q2 		$30K Sell
21,111
-4,989
-19% -$7.26K ﹤0.01% 4200
2025
Q1 		$42K Sell
26,100
-2,780
-10% -$8.29K ﹤0.01% 4081
2024
Q4 		$104K Sell
28,880
-6,290
-18% -$31.3K ﹤0.01% 3897
2024
Q3 		$200K Sell
35,170
-2,927
-8% -$17.6K ﹤0.01% 3703
2024
Q2 		$176K Sell
38,097
-905
-2% -$5.4K ﹤0.01% 3678
2024
Q1 		$319K Buy
39,002
+22,692
+139% +$176K ﹤0.01% 3218
2023
Q4 		$92K Buy
16,310
+839
+5% +$1.91K ﹤0.01% 3685
2023
Q3 		$29K Buy
15,471
+61
+0.4% +$186 ﹤0.01% 3707
2023
Q2 		$42K Hold
15,410
– – ﹤0.01% 3684
2023
Q1 		$48K Buy
15,410
+1,212
+9% +$7.14K ﹤0.01% 3584
2022
Q4 		$83K Buy
14,198
+305
+2% +$2.53K ﹤0.01% 3443
2022
Q3 		$121K Sell
13,893
-817
-6% -$8.48K ﹤0.01% 3328
2022
Q2 		$110K Buy
+14,710
New +$129K ﹤0.01% 3349

Other funds holding CCCC

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return

Commonwealth Equity Services's CCCC Position: Q4 2025 in Review

Commonwealth Equity Services sold out of C4 Therapeutics (CCCC) in Q4 2025, closing a stake of 20,510 shares — an estimated $46K sold.

Commonwealth Equity Services first reported a position in CCCC in Q2 2022 and held it in 14 quarters. The position peaked at $319K in Q1 2024. 101 funds tracked by Wall St. Rank hold CCCC as of Q4 2025.

  • Commonwealth Equity Services reported no remaining C4 Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Commonwealth Equity Services sold 20,510 C4 Therapeutics shares in Q4 2025, an estimated $46K.
  • Commonwealth Equity Services first reported a position in C4 Therapeutics in Q2 2022 and held it in 14 quarters.
  • Commonwealth Equity Services's C4 Therapeutics position peaked at $319K in Q1 2024.
  • 101 funds tracked by Wall St. Rank held C4 Therapeutics as of Q4 2025.

Based on Commonwealth Equity Services's 13F filing for Q4 2025, filed 12 Feb 2026.